Refine
Year of publication
- 2024 (47)
- 2023 (167)
- 2022 (219)
- 2021 (218)
- 2020 (218)
- 2019 (300)
- 2018 (248)
- 2017 (254)
- 2016 (251)
- 2015 (284)
- 2014 (265)
- 2013 (283)
- 2012 (291)
- 2011 (305)
- 2010 (317)
- 2009 (332)
- 2008 (289)
- 2007 (271)
- 2006 (276)
- 2005 (263)
- 2004 (286)
- 2003 (218)
- 2002 (232)
- 2001 (210)
- 2000 (234)
- 1999 (232)
- 1998 (236)
- 1997 (214)
- 1996 (200)
- 1995 (192)
- 1994 (174)
- 1993 (154)
- 1992 (144)
- 1991 (100)
- 1990 (108)
- 1989 (110)
- 1988 (103)
- 1987 (105)
- 1986 (81)
- 1985 (83)
- 1984 (75)
- 1983 (70)
- 1982 (57)
- 1981 (54)
- 1980 (61)
- 1979 (58)
- 1978 (52)
- 1977 (32)
- 1976 (30)
- 1975 (28)
- 1974 (17)
- 1973 (12)
- 1972 (17)
- 1971 (11)
- 1970 (2)
- 1969 (2)
- 1968 (2)
- 1967 (1)
- 1963 (1)
Document Type
- Article (5464)
- Conference Proceeding (1393)
- Book (1056)
- Part of a Book (544)
- Patent (172)
- Bachelor Thesis (156)
- Report (81)
- Doctoral Thesis (78)
- Other (68)
- Contribution to a Periodical (19)
- Master's Thesis (17)
- Review (17)
- Working Paper (8)
- Talk (5)
- Habilitation (4)
- Preprint (4)
- Diploma Thesis (3)
- Poster (3)
- Part of Periodical (2)
- Examination Thesis (1)
Language
Has Fulltext
- no (9096) (remove)
Keywords
- Corporate Design (9)
- Illustration (9)
- Erscheinungsbild (8)
- Gamification (8)
- Nachhaltigkeit (8)
- Redesign (7)
- Animation (6)
- Datenschutz (6)
- Digitalisierung (6)
- avalanche (6)
- App (5)
- Earthquake (5)
- Editorial (5)
- Enterprise Architecture (5)
- Fotografie (5)
- Geschichte (5)
- MINLP (5)
- solar sail (5)
- Aktionskunst (4)
- Design (4)
Institute
- Fachbereich Medizintechnik und Technomathematik (1907)
- Fachbereich Elektrotechnik und Informationstechnik (1116)
- Fachbereich Wirtschaftswissenschaften (1100)
- Fachbereich Energietechnik (1056)
- Fachbereich Chemie und Biotechnologie (829)
- Fachbereich Maschinenbau und Mechatronik (799)
- Fachbereich Luft- und Raumfahrttechnik (749)
- Fachbereich Bauingenieurwesen (658)
- IfB - Institut für Bioengineering (623)
- INB - Institut für Nano- und Biotechnologien (584)
- Solar-Institut Jülich (334)
- Fachbereich Gestaltung (333)
- Fachbereich Architektur (161)
- ECSM European Center for Sustainable Mobility (106)
- MASKOR Institut für Mobile Autonome Systeme und Kognitive Robotik (66)
- Nowum-Energy (64)
- ZHQ - Bereich Hochschuldidaktik und Evaluation (62)
- Institut fuer Angewandte Polymerchemie (32)
- Sonstiges (24)
- IBB - Institut für Baustoffe und Baukonstruktionen (21)
Geld-zurück-Garantien erlangen in der Unternehmenspraxis eine immer größere Bedeutung, vor allem weil sie als probates Mittel zur Signalisierung hochwertiger Qualität angesehen werden – eine Annahme, die bislang wissenschaftlich ungeprüft geblieben ist. Vor diesem Hintergrund wird im vorliegenden Beitrag eine umfassende empirische Untersuchung der kaufverhaltensrelevanten Wirkungen dieses Marketinginstrumentes vorgenommen. Die Ergebnisse verdeutlichen zum einen, dass eine Geld-zurück-Garantie nur unter bestimmten Bedingungen als Qualitätssignal wirkt. Dies hängt neben der Art des Produktes (Erfahrungs- vs. Suchgut) insbesondere von der Ausprägung des für die Qualitätsbeurteilung besonders diagnostischen Merkmals Marke sowie von der Produktkenntnis der Konsumenten ab. Zum anderen zeigt sich aber auch, dass eine Geld-zurück-Garantie affektive Konsumentenreaktionen auslöst, die die Kaufabsicht von Konsumenten zusätzlich erhöhen können. Zusammenfassend stellen wir fest, dass eine Geld-zurück-Garantie – entgegen bisheriger Erwartungen aus der Praxis – nicht zwingend ein Qualitätsindikator ist, stattdessen entfaltet sie aber bisher unbeachtete affektive Wirkungen, die insbesondere auf ihre absichernde Funktion von etwaigen Fehlentscheidungen beim Kauf zurückzuführen sind.
Das Ziel des Deutschen Corporate Governance Kodex (DCGK) besteht in der Verbesserung der Transparenz und Qualität der deutschen Corporate Governance, wobei die Sanktionierung der Nichteinhaltung des DCGK einzig durch etwaige Kapitalmarktreaktionen erfolgt. Folgende Befunde sprechen jedoch dafür, dass durch die Abgabe der Entsprechenserklärung gem. § 161 AktG die für das Enforcement des Kodex angenommene Selbstregulierung durch den Kapitalmarkt nicht stattfindet, und demnach Verbesserungsbedarf besteht
This paper investigates the extent to which corporate governance affects the cost of debt and equity capital of German exchange-listed companies. I examine corporate governance along three dimensions: financial information quality, ownership structure and board structure. The results suggest that firms with high levels of financial transparency and bonus compensations face lower cost of equity. In addition, block ownership is negatively related to firms' cost of equity when the blockholders are other firms, managers or founding-family members. Consistent with the conjecture that agency costs increase with firm size, I find significant cost of debt effects only in the largest German companies. Here, the creditors demand lower cost of debt from firms with block ownerships held by corporations or banks. My findings demonstrate that a uniform set of governance attributes is unlikely to satisfy suppliers of debt and equity capital equally.
BACKGROUND
Immunosuppression is often considered as an indication for antibiotic prophylaxis to prevent surgical site infections (SSI) while performing skin surgery. However, the data on the risk of developing SSI after dermatologic surgery in immunosuppressed patients are limited.
PATIENTS AND METHODS
All patients of the Department of Dermatology and Allergology at the University Hospital of RWTH Aachen in Aachen, Germany, who underwent hospitalization for a dermatologic surgery between June 2016 and January 2017 (6 months), were followed up after surgery until completion of the wound healing process. The follow-up addressed the occurrence of SSI and the need for systemic antibiotics after the operative procedure. Immunocompromised patients were compared with immunocompetent patients. The investigation was conducted as a retrospective analysis of patient records.
RESULTS
The authors performed 284 dermatologic surgeries in 177 patients. Nineteen percent (54/284) of the skin surgery was performed on immunocompromised patients. The most common indications for surgical treatment were nonmelanoma skin cancer and malignant melanomas. Surgical site infections occurred in 6.7% (19/284) of the cases. In 95% (18/19), systemic antibiotic treatment was needed. Twenty-one percent of all SSI (4/19) were seen in immunosuppressed patients.
CONCLUSION
According to the authors' data, immunosuppression does not represent a significant risk factor for SSI after dermatologic surgery. However, larger prospective studies are needed to make specific recommendations on the use of antibiotic prophylaxis while performing skin surgery in these patients.
The available data on complications after dermatologic surgery have improved over the past years. Particularly, additional risk factors have been identified for surgical site infections (SSI). Purulent surgical sites, older age, involvement of head, neck, and acral regions, and also the involvement of less experienced surgeons have been reported to increase the risk of the SSI after dermatologic surgeries.1 In general, the incidence of SSI after skin surgery is considered to be low.1,2 However, antibiotics in dermatologic surgeries, especially in the perioperative setting, seem to be overused,3,4 particularly regarding developing antibiotic resistances and side effects.
Immunosuppression has been recommended to be taken into consideration as an additional indication for antibiotic prophylaxis to prevent SSI after skin surgery in special cases.5,6 However, these recommendations do not specify the exact dermatologic surgeries, and were not specifically developed for dermatologic surgery patients and treatments, but adopted from other surgical fields.6 According to the survey conducted on American College of Mohs Surgery members in 2012, 13% to 29% of the surgeons administered antibiotic prophylaxis to immunocompromised patients to prevent SSI while performing dermatologic surgery on noninfected skin,3 although this was not recommended by Journal of the American Academy of Dermatology Advisory Statement. Indeed, the data on the risk of developing SSI after dermatologic surgery in immunosuppressed patients are limited. However, it is possible that due to the insufficient evidence on the risk of SSI occurrence in this patient group, dermatologic surgeons tend to overuse perioperative antibiotic prophylaxis.
To make specific recommendations on the use of antibiotic prophylaxis in immunosuppressed patients in the field of skin surgery, more information about the incidence of SSI after dermatologic surgery in these patients is needed. The aim of this study was to fill this data gap by investigating whether there is an increased risk of SSI after skin surgery in immunocompromised patients compared with immunocompetent patients.